A Duke Health-led team with collaborators at the University of Minnesota reports that small RNA molecules called piRNAs in blood can strongly predict short-term survival in older adults. The researchers analyzed over 1,200 blood samples from a North Carolina cohort, measured 828 distinct small RNAs and compared those data with 187 clinical factors, linking participants to national mortality records to determine outcomes.
Advanced statistical models and causal artificial intelligence showed that a group of six piRNAs alone predicted two-year survival with accuracy up to 86%, and the result was reproduced in an independent group. Lower levels of specific piRNAs were associated with longer survival, echoing experiments in simple organisms where reducing these molecules extends lifespan. For short-term prognosis, piRNAs outperformed age, cholesterol, physical activity and more than 180 other clinical measures, while lifestyle factors played a larger role for longer-term survival.
Next steps include testing whether treatments, lifestyle changes or medications — including GLP-1-based therapies — can alter piRNA levels and comparing blood piRNA levels with levels inside tissues. Funding for the work came from NIH institutes, including the National Institute on Aging, and the results are published in Aging Cell.
- Analyze whether therapies change piRNA levels
- Compare blood and tissue piRNA measurements
- Validate findings in more groups
Difficult words
- piRNA — a class of small RNAs in cellspiRNAs, piRNA levels
- cohort — a group of people studied together
- prognosis — a prediction of expected health outcome
- causal — relating to cause and effect relationships
- validate — to check that a result is accurate
- outperform — to do better than someone or something elseoutperformed
Tip: hover, focus or tap highlighted words in the article to see quick definitions while you read or listen.
Discussion questions
- How could a blood test for piRNAs change care or decision-making for older adults? Give reasons.
- What are possible benefits and risks of using piRNA-based short-term prognosis in healthcare?
- What kinds of additional groups or studies would you suggest to validate these findings further, and why?
Related articles
Affordable twice-yearly HIV injection lenacapavir to reach 120 countries
Lenacapavir, a twice-yearly HIV prevention injection, will be licensed for 120 low- and middle-income countries at US$40 a year. Rollout is expected from 2027 with funding support, but some countries and price transparency remain concerns.
Teen drug use in the US stays near pandemic low
For the fifth year in a row, use of most substances among US teenagers remains close to the low point reached in 2021, according to the University of Michigan's Monitoring the Future survey. Some drugs rose slightly, and researchers say monitoring must continue.
Gagandeep Kang on Vaccines, Surveillance and Child Health in India
Gagandeep Kang, a leading expert on enteric diseases, urges India to prepare tools to prevent viral outbreaks. She helped develop indigenous rotavirus vaccines, built surveillance networks and now works at the Gates Foundation.
Traditional African Diet Reduces Inflammation
A trial in Tanzania found that a traditional plant-based African diet lowered inflammation within two weeks, while a short-term Western diet increased inflammation and weakened immune responses. The results matter for rising non-communicable diseases in Sub-Saharan Africa.